Shelter Pharma (543963) Q4 21/22 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 21/22 earnings summary
23 Oct, 2026Executive summary
FY22 revenue and profit increased from FY21 levels; net profit was Rs 18,56,94,467, and no dividend was recommended.
Manufacturing of pharmaceutical products, including animal food supplements, remained the core business.
Financial highlights
Revenue from operations: Rs 30,05,54,480 in FY22 vs Rs 22,48,34,410 in FY21.
Profit before depreciation and tax: Rs 2,91,94,058; depreciation: Rs 16,87,889; profit after tax: Rs 1,85,69,467 vs Rs 5,09,944 in FY21.
Audited statement reports profit before tax of Rs 2,75,06,169 vs Rs 6,84,944 in FY21; tax expense included Rs 90,94,866 current tax and Rs 1,58,164 deferred tax.
Outlook and guidance
Management expected sales affected by COVID-related travel and transportation constraints to recover in the near future; no quantified forecast was stated.
Latest events from Shelter Pharma
- Revenue and net profit rose in FY18; profits were retained and no dividend recommended.543963
Q4 17/18 - Revenue declined, but FY19 net profit and EPS improved; no dividend was recommended.543963Q4 18/19
- Revenue and PAT rose in FY20 as factory expansion advanced; Rs 3 crore of advances were written off.543963Q4 19/20
- COVID disruption cut sales as FY21 profit fell; ₹30 lakh of old advances was written off.543963Q4 20/21
- FY23 profit rose, while receivables climbed and an IPO of up to ₹350m advanced.543963Q4 22/23
- Strong revenue and profit growth, full utilization of raised funds, and clean audit opinion.543963Q4 25/26
- Revenue and profit increased year-over-year, with all raised funds used as intended.543963Q2 25/26
- Revenue and net profit grew year-over-year, with EPS rising to ₹3.06.543963Q2 24/25
- Revenue and net profit rose year-over-year, with robust financials and new auditor appointments.543963Q4 24/25